data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
SPY
––%
QQQ
––%
BTC/USD
––%
DIA
––%
GLD
––%
TLT
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Alternative Investment Platforms
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
Watch
YouTube
Podcasts
Trading School
My Stocks
Tools
Premium
SPY
––%
QQQ
––%
BTC/USD
––%
DIA
––%
GLD
––%
TLT
––%
Alimera Sciences
(NASDAQ:ALIM)
$5.88
0.15[2.62%]
At close: Oct 6
$6.71
0.8300[14.12%]
After Hours: 9:30AM EDT
Day Range5.76 - 6.1252 Wk Range3.94 - 7.92Open / Close5.83 / 6.12Float / Outstanding4.5M / 7M
Vol / Avg.5.8K / 15KMkt Cap41.1MP/E-50d Avg. Price6.35
Div / Yield-Payout Ratio-Total Float4.5MEPS-0.45

Alimera Sciences Stock (NASDAQ:ALIM), Quotes and News Summary

Alimera Sciences Stock (NASDAQ: ALIM)

Day Range5.76 - 6.1252 Wk Range3.94 - 7.92Open / Close5.83 / 6.12Float / Outstanding4.5M / 7M
Vol / Avg.5.8K / 15KMkt Cap41.1MP/E-50d Avg. Price6.35
Div / Yield-Payout Ratio-Total Float4.5MEPS-0.45
Sector: Health Care.Industry: Pharmaceuticals
Alimera Sciences Inc is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology. The company expects to accelerate growth of ILUVIEN through increased penetration of existing markets; expansion into new markets; and a new indication for non-infectious posterior uveitis in the EU.
Read More

Earnings

see more
Q3 2022Est.ActualSurprise
EPS
(EXPECTED)2022-10-27
REV
Q2 2022Est.ActualSurprise
EPS-0.550-0.450 0.1000
REV13.140M14.604M1.464M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Alimera Sciences Questions & Answers

Q
How do I buy Alimera Sciences (ALIM) stock?
A

You can purchase shares of Alimera Sciences (NASDAQ: ALIM) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Alimera Sciences's (ALIM) competitors?
Q
What is the target price for Alimera Sciences (ALIM) stock?
A

The latest price target for Alimera Sciences (NASDAQ: ALIM) was reported by HC Wainwright & Co. on Thursday, July 28, 2022. The analyst firm set a price target for 9.00 expecting ALIM to rise to within 12 months (a possible 53.06% upside). 3 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Alimera Sciences (ALIM)?
A

The stock price for Alimera Sciences (NASDAQ: ALIM) is $5.88 last updated Today at October 6, 2022, 8:00 PM UTC.

Q
Does Alimera Sciences (ALIM) pay a dividend?
A

There are no upcoming dividends for Alimera Sciences.

Q
When is Alimera Sciences (NASDAQ:ALIM) reporting earnings?
A

Alimera Sciences’s Q3 earnings are confirmed for Thursday, October 27, 2022.

Q
Is Alimera Sciences (ALIM) going to split?
A

There is no upcoming split for Alimera Sciences.

Q
What sector and industry does Alimera Sciences (ALIM) operate in?
A

Alimera Sciences is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.